

Step Therapy Criteria
Farm Bureau Select Health Plan
Date Effective: July 1, 2022

ANTIDEPRESSANTS - SCORE

Products Affected

- Emsam
- Fetzima
- Fetzima Titration Pack
- Sertraline Hydrochloride CAPS

Details

Criteria	Trial of two generics of the following formulary products: bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline (tablet or solution), venlafaxine. Approve for continuation of prior therapy.
-----------------	---

ATYPICAL ANTIPSYCHOTICS - SCORE

Products Affected

- Caplyta
- Fanapt
- Fanapt Titration Pack
- Lybalvi
- Vraylar

Details

Criteria	Trial of two of the following oral generic formulary atypical antipsychotic agents: aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone. Approve for continuation of prior therapy. Step requirement does not apply for Caplyta if request is for depressive episodes associated bipolar I or II disorder.
-----------------	---

GLUCAGON- SCORE

Products Affected

- Glucagen Hypokit

Details

Criteria	Trial of one of the following: Gvoke, Baqsimi, or Glucagon
----------	--

INHALED CORTICOSTEROID - SCORE

Products Affected

- Qvar Redihaler

Details

Criteria	Trial of: Arnuity Ellipta and either Flovent Diskus or Flovent HFA
----------	--

INVEGA HAFYERA THERAPY - SCORE

Products Affected

- Invega Hafyera

Details

Criteria	Trial of one of the following: Invega Sustenna or Invega Trinza. Step applies to new starts only. Approve for continuation of prior therapy.
-----------------	--

NAMZARIC - SCORE

Products Affected

- Namzarin

Details

Criteria	Trial of generic memantine extended-release
----------	---

NON-PREFERRED SGLT2s - SCORE

Products Affected

- Invokana

Details

Criteria	Trial of Farxiga or Xigduo XR, AND one of the following: Jardiance, Synjardy, Synjardy XR. Step requirements do not apply to members with type 2 diabetes with either diabetic nephropathy or established cardiovascular disease.
-----------------	---

PD AGENTS - SCORE

Products Affected

- Neupro

Details

Criteria	Trial of one of the following generic formulary dopamine agonist agent: pramipexole, ropinirole
-----------------	--

RELISTOR - SCORE

Products Affected

- Relistor

Details

Criteria	Trial of lubiprostone or lactulose
-----------------	------------------------------------

SKIN CANCER AGENTS - SCORE

Products Affected

- Diclofenac Sodium GEL 3%
- Picato

Details

Criteria	Trial of fluorouracil or imiquimod
-----------------	------------------------------------

STATINS - SCORE

Products Affected

- Livalo

Details

Criteria	Trial of any one of the following generic formulary HMG-CoA reductase inhibitors (statin): atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin
-----------------	--

INDEX

A	
Antidepressants - Score.....	1
Atypical Antipsychotics - Score.....	2
C	
Caplyta	2
D	
Diclofenac Sodium.....	10
E	
Emsam.....	1
F	
Fanapt.....	2
Fanapt Titration Pack	2
Fetzima.....	1
Fetzima Titration Pack	1
G	
Glucagen Hypokit	3
Glucagon- Score.....	3
I	
Inhaled Corticosteroid - Score.....	4
Invega Hafyera	5
Invega Hafyera Therapy - Score	5
Invokana.....	7
L	
Livalo	11
Lybalvi	2
N	
Namzaric.....	6
Namzaric - Score.....	6
Neupro.....	8
Non-preferred Sglt2s - Score	7
P	
Pd Agents - Score.....	8
Picato.....	10
Q	
Qvar Redihaler	4
R	
Relistor.....	9
Relistor - Score	9
S	
Sertraline Hydrochloride.....	1
Skin Cancer Agents - Score	10
Statins - Score	11
V	
Vraylar	2